| Remicade (infliximab) / J&J |
2012-002702-51: Discontinuation of biologic therapy (infliximab) in patients with Crohn’s disease during sustained complete absence of disease activity: A Nordic multi-center, double blinded, randomized, placebo controlled study |
|
|
| Ongoing | 4 | 136 | Europe | Remicade, Remsima, EMEA/H/C/002778, Concentrate for solution for infusion, Remicade, Remsima | Department of medical gastroenterology S, Odense University Hospital, Department of medical gastroenterology, Herlev Hospital, Norforsk/ Region Hovedstadens forskningsfond/ other independent funds | Patients with Crohn's disease with absence of disease activity during biologic therapy (infliximab), Patients with inflammatory bowel disease (Crohn's disease) with absence of disease activity during treatment with a biologic agent., Diseases [C] - Digestive System Diseases [C06] | | | | |
2011-001332-29: The degradation and elimination of Infliximab Die Elimination und der Abbau von Infliximab |
|
|
| Ongoing | 4 | 200 | Europe | Remicade, Powder for solution for injection/infusion, Remicade | Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie | Inflammatory bowel disease (Ulcerative Colitis, Crohn's disease) chronisch entzündliche Darmerkrankungen (Colitis Ulcerosa, Morbus Crohn), chronic inflammatory bowel disease chronisch entzündliche Darmerkrankungen, Diseases [C] - Digestive System Diseases [C06] | | | | |
2008-005619-16: Impact of anti-tumor necrosis factors antibodies treatment on fertility of inflammatory bowel diseases male patients |
|
|
| Ongoing | 4 | 100 | Europe | infliximab, adalimumab, | Erasmus Medical Center | Fertility influenced by antiTNF treatment | | | | |
2007-005464-26: Devlopment of Heart and blood vessel problems in patients with conditions which cause long-term, widespread, inflammation in the body. |
|
|
| Ongoing | 4 | 100 | Europe | Cimzia, Remicade, Enbrel, Humira, Cimzia, Remicade, Enbrel, Humira, Cimzia | Kings College London, Guys and St Thomas\'NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust BRC | Rheumatoid Arthritis | | | | |
ACTRN12616001031459: PROxIMO: Efficacy of proactive therapeutic drug monitoring and dose adjustment of infliximab based on point of care testing for inflammatory bowel disease |
|
|
| Active, not recruiting | 4 | 80 | | | Alfred Health Pharmacy Department, Alfred Hospital Pharmacy Department, Buhlmann Laboratories AG | Ulcerative Colitis, Crohn's Disease | | | | |
2018-002925-47: prediction of response to therapy in inflammatory bowel disease Predicción de respuesta al tratamiento en la enfermedad inflamatoria intestinal |
|
|
| Not yet recruiting | 4 | 180 | Europe | Injection, Infusion, Adalimumab, Infliximab, Golimumab, Ustekinumab, Vedolizumab | Fundación de Investigación Biomédica del Hospital Universitario de La Princesa, Instituto de Salud Carlos III | Inflammatory bowel disease Enfermedad inflamatoria intestinal, Corhn´s disease and ulcerative colitis Enfermedad de Crohn y colitis ulcerosa, Diseases [C] - Digestive System Diseases [C06] | | | | |
2018-004587-61: Characterization of lipid changes in patients with ulcerative colitis treated with tofactinib or infliximab Karakteriseren van veranderingen die optreden in vetten bij patiënten met colitis ulcerosa tijdens de behandeling met tofacitinib of infliximab |
|
|
| Ongoing | 4 | 40 | Europe | Tofacitinib, Infliximab, Film-coated tablet, Concentrate and solvent for solution for infusion, Xeljanz, Inflectra | Erasmus Medical Center, Erasmus Medical Center, Pfizer | Ulcerative colitis Colitis ulcerosa, Chronic inflammatory bowel disease of the large intestine and rectum Chronische ontstekingsziekte van de dikke darm en endeldarm, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT03004443: Inflammation-Induced CNS Glutamate Changes in Depression |
|
|
| Terminated | 4 | 22 | US | Infliximab, Remicade, Placebo, Saline solution | Emory University, National Institute of Mental Health (NIMH) | Depression | 11/19 | 11/19 | | |
2019-002942-19: Nordic study of treatment strategy in inflammatory bowel disease Nordisk studie av behandlingsstrategi vid inflammatorisk tarmsjukdom |
|
|
| Ongoing | 4 | 300 | Europe, RoW | Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Film-coated tablet, Tablet, Remicade Infliximab, Humira Adalimumab, Imurel Azatioprin, Puri-nethol Merkaptopurin | Region Örebro län, VINNOVA | Crohn's disease and Ulcerative colitis, Crohn's disease and Ulcerative colitis, Diseases [C] - Digestive System Diseases [C06] | | | | |
2020-004012-10: Model-informed prolonging of the infliximab dosing interval after an earlier shortening of the dosing interval in adult patients with inflammatory bowel diseases |
|
|
| Not yet recruiting | 4 | 40 | Europe | infliximab, Powder for concentrate for solution for infusion, Inflectra | UZ Leuven, UZ Leuven, Department of Gastroenterology and Hepatology, KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies | Inflammatory bowel diseases- Crohn's disease- ulcerative colitis, Inflammatory bowel diseases- Crohn's disease- ulcerative colitis, Diseases [C] - Digestive System Diseases [C06] | | | | |
2021-000570-28: Accelerated infliximab infusions in inflammatory bowel disease Nopeutetut infliksimabi-infuusiot tulehduksellisissa suolisairauksissa |
|
|
| Not yet recruiting | 4 | 130 | Europe | infliximab, Infusion, Zessly, Remsima, Remicade | Tampere University Hospital, Tampere University Hospital | Inflammatory bowel diseases Tulehdukselliset suolistosairaudet, Inflammatory bowel diseases Tulehdukselliset suolistosairaudet, Diseases [C] - Digestive System Diseases [C06] | | | | |
| Completed | 4 | 139 | Europe | Anti-TNF: Infliximab (Infusion), Anti-TNF discontinuation: Physiological saline solution, Anti-TNF:Adalimumab (Subcutaneus) | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis | 12/21 | 12/22 | | |
2021-003220-32: Modulation of infliximab therapy based on blood drug levels in pediatric inflammatory bowel disease. Modulazione della terapia con infliximab in base ai livelli ematici di farmaco nelle malattie infiammatorie croniche intestinali pediatriche. |
|
|
| Not yet recruiting | 4 | 86 | Europe | infliximab, [N.A.], Powder for concentrate for solution for infusion | IRCCS MATERNO INFANTILE BURLO GAROFOLO, IRCCS BURLO GAROFOLO | Pediatric Inflammatory Bowel Disease Malattie infiammatorie croniche intestinali pediatriche, Pediatric Inflammatory Bowel Disease Malattie infiammatorie croniche intestinali pediatriche, Diseases [C] - Digestive System Diseases [C06] | | | | |
MODIFI, NCT04982172: Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases |
|
|
| Completed | 4 | 80 | Europe | Infliximab | Universitaire Ziekenhuizen KU Leuven, KU Leuven | Inflammatory Bowel Diseases | 11/22 | 02/23 | | |
| Completed | 4 | 96 | US | Infliximab | Washington University School of Medicine | Inflammatory Bowel Diseases | 05/23 | 05/23 | | |
| Enrolling by invitation | 4 | 148 | Europe | Infliximab, Remicade, Flixabi, Inflectra, Remsima, Zessly, Adalimumab, Humira, AMGEVITA, Hulio, Hyrimoz, Idacio, Imraldi | University Medical Center Groningen, European Crohn´s and Colitis Organisation, Bühlmann Laboratories AG | Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative | 03/25 | 03/25 | | |
BioIBD, NCT03885713: Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease |
|
|
| Recruiting | 4 | 180 | Europe | Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis | 12/24 | 12/24 | | |
EPIC, NCT05280405: Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: Study |
|
|
| Recruiting | 4 | 86 | Europe | Infliximab | IRCCS Burlo Garofolo | Inflammatory Bowel Diseases | 01/24 | 01/25 | | |
NCT03591770: Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib |
|
|
| Terminated | 4 | 15 | US | SHINGRIX, Recombinant zoster vaccine | Boston Medical Center | Inflammatory Bowel Diseases | 07/24 | 07/24 | | |
OPTIMIZE, NCT04835506: Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The Trial |
|
|
| Enrolling by invitation | 4 | 196 | Canada, US | Infliximab | Beth Israel Deaconess Medical Center, The Leona M. and Harry B. Helmsley Charitable Trust, Icahn School of Medicine at Mount Sinai | Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases | 12/24 | 12/24 | | |
| Recruiting | 4 | 20 | US | Infliximab, Placebo | Emory University, National Institute of Mental Health (NIMH) | Schizophrenia | 03/28 | 03/28 | | |
ACTRN12619001081101p: Concentrated Albumin Prior to Rescue Infliximab (CAPRI) in Acute Severe Ulcerative Colitis (ASUC) |
|
|
| Not yet recruiting | 2 | 30 | | | Alfred Hospital, Alfred Hospital | Ulcerative colitis; Inflammatory Bowel Disease | | | | |
ACTRN12619001081101: Concentrated Albumin Prior to Rescue Infliximab (CAPRI) in Acute Severe Ulcerative Colitis (ASUC) |
|
|
| Not yet recruiting | 2 | 30 | | | Alfred Hospital, Alfred Hospital | Ulcerative colitis, Inflammatory Bowel Disease | | | | |
2011-003630-13: Tracer for the imaging of disease activity in sarcoidosis in the lung |
|
|
| Ongoing | 2 | 15 | Europe | 99mTc-Infliximab, not applicable, Radiopharmaceutical precursor, solution | Sint Antonius Hospital, Sint Antonius Hospital | Pulmonary sarcoidosis, Inflammatory disease of the lungs., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2017-003311-19: Phase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximabAIH-MAB Phase IIa proof-of-principle Studie zur Wirksamkeit von Infliximab in der Induktionstherapie der Autoimmunen Hepatitis |
|
|
| Ongoing | 2 | 12 | Europe | Concentrate for solution for infusion, Inflectra (Infliximab) | University Medical Centre Hamburg-Eppendorf, University Medical Centre Hamburg-Eppendorf | Autoimmune Hepatitis (AIH); rare inflammatory liver disease associated with elevated transaminases, elevated Immunoglobulin G, the presence of autoantibodies and interface hepatitis in liver histology. Untreated, AIH progresses to liver fibrosis and cirrhosis with its complications. Historical placebo-controlled studies could show a mortality of around 70% in the placebo-treated group. Die Autoimmune Hepatitis ist eine chronische Entzündung der Leber, die durch eine Reaktion des Immunsystems gegen körpereigenes Lebergewebe ausgelöst wird. Die Ursachen hierfür sind bisher unklar. Die Behandlung der autoimmunen Hepatitis besteht in der Therapie mit sogenannten Immunsuppressiva, also Medikamenten, die das körpereigene Immunsystem schwächen und so die Reaktion gegen das körpereigene Lebergewebe unterdrücken., Autoimmune Hepatitis (AIH) is rare inflammatory liver disease caused by unknown triggers. Untreated, AIH progresses to to liver fibrosis and cirrhosis with its complications Die Autoimmune Hepatitis ist eine chronische Entzündung der Leber, die durch eine Reaktion des Immunsystems gegen körpereigenes Lebergewebe ausgelöst wird. Die Ursachen hierfür sind bisher unklar., Diseases [C] - Immune System Diseases [C20] | | | | |
COMBO-UC, NCT06453317: Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis |
|
|
| Not yet recruiting | 2 | 172 | NA | Infliximab, Ustekinumab | Medical University of Lodz, Poznan University of Medical Sciences, Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań, Norbert Barlicki Memorial Teaching Hospital No. 1 of the Medical University of Lodz, Medical Research Agency, Poland | Ulcerative Colitis, Inflammatory Bowel Diseases | 04/28 | 06/28 | | |
NCT04331639: High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy |
|
|
| Recruiting | 2 | 50 | US | vitamin D3, cholecalciferol | Boston Children's Hospital | Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency | 09/24 | 09/24 | | |
NCT06136546: Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab |
|
|
| Not yet recruiting | 2 | 100 | NA | Infliximab, Placebo | Massachusetts General Hospital | Depressive Disorder, Major, Inflammation | 09/27 | 09/27 | | |
| Terminated | 2 | 1 | US | Infliximab, Remicade, Intravenous Immunoglobulin Therapy, Gamma Globulin, Gamma Globulin Therapy, Immune Globulin, Immune Globulin Therapy, Intravenous Immunoglobulin, IVIG, Prednisone, Deltasone, Orasone, Meticorten, Panasol-S, Liquid-Pred, Methylprednisolone, Methylprednisolone sodium succinate (Solu-Medrol), methylprednisolone acetate (Depo-Medrol), Methylprednisolone (Medrol) | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis | 12/23 | 12/23 | | |
NCT04082910: Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells |
|
|
| Recruiting | 1/2 | 30 | RoW | Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents | Chinese PLA General Hospital | Solid Tumor, Hematological Malignancy | 12/22 | 12/23 | | |
NCT04407247: Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma |
|
|
| Recruiting | 1/2 | 100 | US | Infliximab, Avakine, cA2, Remicade, Remsima, Vedolizumab, Entyvio, Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer''s patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer, LDP 02, LDP-02, LDP02, MLN0002, MLN02 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Melanoma | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 800 | US | Best Practice, standard of care, standard therapy, Biospecimen Collection, Endoscopic Procedure, Endoscopic Examination, Endoscopy, Fecal Microbiota Transplantation, Fecal Material Transplantation, Fecal Transplantation, FMT, Poo Transplant, Poop Transplant, Stool Transplant, Infliximab, Avakine, cA2, Remicade, Remsima, Laboratory Biomarker Analysis, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vedolizumab, Entyvio, Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer''s patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer, LDP 02, LDP-02, LDP02, MLN0002, MLN02 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Pathologic Stage 0 Cutaneous Melanoma AJCC v8, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8 | 10/25 | 10/25 | | |
| Completed | 1 | 33 | Europe | Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab, Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab | Institut Claudius Regaud | Melanoma | 12/19 | 08/23 | | |
ChiCTR-CCC-10001054: Circulating Dickkopf-1 (DKK-1) is Correlated with Bone Erosion and Inflammation in Rheumatoid Arthritis |
|
|
| Completed | N/A | 78 | | none ;Infliximab | National Sciences Foundation of China; Level of the institution：, National Basic Research Program of China (Grant No. 2010CB529100) and the National Sciences Foundation of China (Grant No.30972710) | ra | | | | |
| Active, not recruiting | N/A | 210 | Europe | | Helse Stavanger HF, Rikshospitalet University Hospital, Oslo University Hospital | Inflammatory Bowel Disease | 11/15 | 12/24 | | |
| Completed | N/A | 1109 | Europe | | Nantes University Hospital | IBD, COVID | 02/21 | 02/21 | | |
NCT05777616: The Impact of Medication Belief on Adherence to Infliximab in Patients With Crohn's Disease |
|
|
| Completed | N/A | 166 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Inflammatory Bowel Diseases | 12/21 | 12/21 | | |
| Active, not recruiting | N/A | 30 | US | Transcutaneous Electrical Nerve Stimulation (TENS) | Northwell Health | Crohn Disease, Ulcerative Colitis | 12/22 | 12/23 | | |
ChiCTR2300073537: Improved outcomes for pediatric patients with inflammatory bowel disease receiving proactive therapeutic drug monitoring of infliximab |
|
|
| Completed | N/A | 57 | | The treatment group adjusts the treatment plan based on IFX concentration; During the treatment period, there will be no monitoring of IFX blood drug concentration and ATI, and empirical medication adjustments will be made based on clinical, biochemical, endoscopic results. | Shengjing Hospital of CMU; Shengjing Hospital, [Basic Research Projects of Liaoning Provincial Department of Education in 2022] under Grant [LJKMZ20221184] from Jing Guo, [Science and Technology Plan of Liaoning Province] under Grant [2021JH2/10300094]and 345 Talent Project from Lingfen Xu. | IBD | | | | |
NCT04761952: N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease |
|
|
| Not yet recruiting | N/A | 236 | NA | azathioprine, AZA, infliximab, IFX, N-3 Polyunsaturated Fatty Acids, n-3PUFA | Sixth Affiliated Hospital, Sun Yat-sen University | Inflammatory Bowel Diseases, Crohn Disease, Polyunsaturated Acid Lipidosis | 12/22 | 12/23 | | |
NCT05291039: Infliximab and Adalimumab in Inflammatory Bowel Disease Patients. |
|
|
| Completed | N/A | 56 | RoW | Infliximab, IFX, Adalimumab, ADA | Rehab Werida | Inflammatory Bowel Diseases | 03/23 | 04/23 | | |
PEREM, NCT04990258: A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC |
|
|
| Active, not recruiting | N/A | 444 | Europe | Subcutaneous infliximab CT-P13 Remsima®SC | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Celltrion | Inflammatory Bowel Diseases | 06/24 | 09/24 | | |
INHERIT, NCT04109300: Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease |
|
|
| Not yet recruiting | N/A | 162 | Canada | HLADQA1*05A>G screening, Standard of Care | Western University, Canada | Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease | 09/23 | 09/23 | | |
BIOES, NCT06604728: Effectiveness and Tolerance of IV vs SC Biological Drugs in Gastrointestinal Diseases |
|
|
| Recruiting | N/A | 400 | Europe | | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Inflammatory Bowel Diseases | 09/25 | 09/25 | | |
NCT05719389: EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM I.V. FORMULATION OF INFLIXIMAB |
|
|
| Recruiting | N/A | 250 | Europe | CT-P13 | IRCCS San Raffaele | Inflammatory Bowel Diseases, Rheumatologic Disease | 10/23 | 04/25 | | |
| Active, not recruiting | N/A | 750000 | Europe | | Assistance Publique - Hôpitaux de Paris | Inflammatory Disease | 12/23 | 01/24 | | |
ChiCTR2000033770: Microbial mechanism of biologics in the prevention and treatment of inflammatory bowel disease |
|
|
| Not yet recruiting | N/A | 200 | | nil ;nil | Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital, Genaral Program of Natural Nature Science Foundation of China | Inflammatory bowel disease | | | | |
NCT05014555: Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease |
|
|
| Not yet recruiting | N/A | 400 | US | COVID-19 Vaccine | GI Alliance, Janssen, LP, University of Wisconsin, Madison, Mayo Clinic | Inflammatory Bowel Diseases | 01/24 | 01/24 | | |
NCT06269185: Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis |
|
|
| Recruiting | N/A | 270 | Europe | Infliximab, Adalimumab | Vastra Gotaland Region | Ulcerative Colitis, Inflammatory Bowel Diseases | 03/25 | 03/25 | | |
NCT04921670: Infliximab Proactive Drug Monitoring in the Pediatric IBD Population |
|
|
| Active, not recruiting | N/A | 60 | US | Infliximab Assay | Cares, Kristen, M.D. | Inflammatory Bone Disease | 03/25 | 08/25 | | |
NCT06033469: Therapeutic Monitoring of Infliximab and Adalimumab |
|
|
| Recruiting | N/A | 100 | Europe | Infliximab, Adalimumab | IRCCS Burlo Garofolo | Inflammatory Bowel Diseases | 06/24 | 06/24 | | |
NCT06601595: Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital |
|
|
| Not yet recruiting | N/A | 100 | NA | TNF inhibitors, conventional ibd medical treatment | Mohamed Nasr | Inflammatory Bowel Disease (IBD), Spondylarthropathies, TNF-alpha Inhibitors | 01/26 | 03/26 | | |
SPACIFIX, NCT03841942: Comparison of Trough Level- and Clinical-based Spacing of Infliximab Infusions in Patients With IBD in Deep Remission |
|
|
| Terminated | N/A | 64 | Europe | clinically-based spacing strategy, Trough level-based strategy | University Hospital, Montpellier | Inflammatory Bowel Diseases | 10/23 | 10/23 | | |
NCT02332460: Infusion Related Reactions in Patients Receiving Infliximab |
|
|
| Active, not recruiting | N/A | 125 | Europe | | Haukeland University Hospital | Chronic Inflammatory Disease | 01/25 | 01/25 | | |
NeuMRA, NCT04378621: Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients |
|
|
| Active, not recruiting | N/A | 212 | Europe | TNF-α inhibitor OR JAK inhibitor, TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi), JAK-inhibitors: Baricitinib (Olumiant), Tofacitinib (Xeljanz), Hand training, physiotherapy of hands | Vastra Gotaland Region | Rheumatoid Arthritis, Pain, Fatigue, Cognitive Decline, Depression, Brain Diseases, Hand Rheumatism | 09/25 | 09/25 | | |
NCT03358693: Molecular Signatures in Inflammatory Skin Disease |
|
|
| Recruiting | N/A | 300 | Europe | Ustekinumab, Infliximab, Secukinumab, Dupilumab, Brodalumab, Ixekizumab, Baricitinib, Abrocitinib, Upadacitinib, Tralokinumab | Prof. Dr. Stephan Weidinger | Atopic Dermatitis, Psoriasis | 12/27 | 12/28 | | |
| Recruiting | N/A | 2000 | US | Methotrexate, Sulfasalazine, Azulfidine, Leflunomide, areva, Pamidronate, Aredia, Zoledronic acid, Etanercept, enbrel, Adalimumab, humira, Certolizumab, cimzia, Infliximab, remicade, inflectra, Golimumab, simponi, NSAID | Seattle Children's Hospital, Boston Children's Hospital, Boston, MA, USA, Hospital for Special Surgery, New York, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA, Riley Children's Hospital, Indianapolis, IN, USA, University of North Carolina, Chapel Hill, NC, USA, Royal Children's Hospital, Melbourne, Australia, Hacettepe University, Ankara, Turkey, Bambino Gesù Children's Hospital, Rome, Italy, University of British Columbia, Vancouver, BC, Canada, Meyer Children's Hospital, Florence, Italy, Mansoura University, University of Utah, Salt Lake City, UT, USA, University of Iowa Carver College of Medicine, Iowa City, IA, USA, Ann & Robert Lurie Children's Hospital of Chicago, Chicago, IL, USA, Palacky University Olomouc Institute of Molecular and Translational Medicine, Olomouc, Czechia, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK, University of Calgary, Calgary, Alberta, Canada | Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis | 08/28 | 08/50 | | |
DEVELOP, NCT00606346: A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease |
|
|
| Active, not recruiting | N/A | 4970 | Canada, US | Anti TNF therapy including infliximab, No Biologics | Janssen Biotech, Inc. | Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases | 11/37 | 06/38 | | |
|
NCT05406934: Evaluation of Blood Platelet Indices,Platelet Aggregation in the Activity of IBD Patients on Biological Treatment |
|
|
| Not yet recruiting | N/A | 120 | NA | Infliximab | Assiut University | Bowel Disease, Inflammatory Bowel Diseases | 06/22 | 10/24 | | |
